The efforts will study the efficacy of Amrana's SV40-based gene delivery vector platform (Svec) for downregulation of pathological immune responses underlying the destruction of host cells in DM1 and MS patients. The studies will use advanced animal models of both autoimmune diseases to evaluate Svec-mediated immune tolerance to primary self-antigens.
Armana will invest nearly $700,000 over the next two years in the research to conduct proof-of-principle studies for the two indications. The research will be conducted at the Cabimer research institute led by Benoit Gauthier, PhD, and Armana's Peter de Haan, PhD, and Miguel García Toscano, PhD.
Copyright © 2020 scienceboard.net